GlassScriptPhysician profile
Charles S Jennisch
NPI 1225133606
$948,570.75
in general payments reported to CMS, 2019-2025
22 companies · $178K in 2025
The $178K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143K · 2020: $26K · 2021: $92K · 2022: $141K · 2023: $220K · 2024: $149K · 2025: $178K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $349K · Consulting Fee: $150K · Travel and Lodging: $37K · Food and Beverage: $11K · Education: $12.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $348,587.00 |
| Consulting Fee | $150,477.00 |
| Travel and Lodging | $37,413.03 |
| Food and Beverage | $10,735.67 |
| Education | $12.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $472,184.82 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $149,884.13 | 2020-2025 | Caplyta |
| Axsome Therapeutics, INC. | $134,134.06 | 2022-2024 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $67,888.74 | 2023-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $47,407.83 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $40,065.72 | 2019-2023 | Trintellix |
| Janssen Pharmaceuticals, INC | $21,797.39 | 2019-2025 | Spravato |
| Allergan, INC. | $8,215.93 | 2019 | |
| Sunovion Pharmaceuticals INC. | $3,553.13 | 2019-2022 | |
| Alkermes, INC. | $1,353.16 | 2022 | |
| Idorsia Pharmaceuticals US INC | $1,190.00 | 2023 | Quviviq |
| Jazz Pharmaceuticals INC. | $147.44 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $135.08 | 2020-2023 | Austedo Xr |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $125.38 | 2019-2023 | Rexulti |
| Ironshore Pharmaceuticals INC. | $124.25 | 2019-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $103.26 | 2019-2022 | |
| Abbvie INC. | $64.84 | 2021-2025 | |
| Bausch Health US, LLC | $63.02 | 2019 | |
| Shire North American Group INC | $50.04 | 2019 | |
| Lundbeck LLC | $38.79 | 2021-2024 | Rexulti |
| Corium, LLC | $22.23 | 2022 | |
| Supernus Pharmaceuticals, INC. | $21.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Jennisch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.